Venus Medtech (HKG:2500) said it is not aware of any undisclosed inside information following media reports about a patent infringement lawsuit involving its U.S. subsidiary, according to a Tuesday Hong Kong bourse filing.
The company made the clarification after the Hong Kong Stock Exchange requested a response to a press article on litigation filed by Cardiovalve and MTH IP against Edwards Lifesciences in a U.S. federal court, the filing said.
Shares of the firm were down more than 6% in Tuesday afternoon trade.